tranexamic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2713 1197-18-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tranexamic acid
  • amchafibrin
  • amikapron
  • cyclocapron
  • tranol
  • transamin
  • zataranax
Antifibrinolytic hemostatic used in severe hemorrhage.
  • Molecular weight: 157.21
  • Formula: C8H15NO2
  • CLOGP: -1.80
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 63.32
  • ALOGS: -0.94
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O
2 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 34 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.38 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.97 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1986 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Purpura 83.90 17.37 39 8891 9872 50586322
Melaena 82.25 17.37 54 8876 26810 50569384
Pulmonary embolism 73.35 17.37 90 8840 101614 50494580
Renal cortical necrosis 72.22 17.37 13 8917 92 50596102
Wrong product administered 67.85 17.37 28 8902 5332 50590862
Vaginal haemorrhage 67.11 17.37 46 8884 24505 50571689
Heavy menstrual bleeding 62.09 17.37 37 8893 15500 50580694
Rash maculo-papular 56.96 17.37 43 8887 26598 50569596
Status epilepticus 56.39 17.37 33 8897 13373 50582821
Vasodilatation 50.84 17.37 18 8912 2261 50593933
Myoclonus 48.99 17.37 31 8899 14439 50581755
Haemorrhage 48.03 17.37 53 8877 53388 50542806
Thrombocytopenia 45.37 17.37 81 8849 127592 50468602
Rectal haemorrhage 45.02 17.37 44 8886 38514 50557680
Hereditary angioedema 44.77 17.37 21 8909 5421 50590773
Cerebral infarction 42.08 17.37 33 8897 21571 50574623
Deep vein thrombosis 42.08 17.37 58 8872 73246 50522948
Platelet count decreased 41.16 17.37 68 8862 100658 50495536
Biliary sepsis 40.74 17.37 12 8918 838 50595356
Generalised tonic-clonic seizure 40.40 17.37 35 8895 26275 50569919
Anaphylactic reaction 37.57 17.37 47 8883 54008 50542186
Aplastic anaemia 35.15 17.37 20 8910 7683 50588511
Acute left ventricular failure 32.50 17.37 10 8920 811 50595383
Tri-iodothyronine free decreased 31.94 17.37 8 8922 302 50595892
Infusion site scar 31.30 17.37 8 8922 328 50595866
Retinal artery occlusion 30.36 17.37 11 8919 1476 50594718
Fatigue 30.36 17.37 49 8881 707552 49888642
Rash erythematous 30.33 17.37 34 8896 34818 50561376
Epistaxis 29.99 17.37 46 8884 63908 50532286
Haemoglobin decreased 29.93 17.37 68 8862 127148 50469046
Brain oedema 28.74 17.37 21 8909 12349 50583845
Drug hypersensitivity 28.47 17.37 5 8925 251005 50345189
Basophil count increased 28.19 17.37 9 8921 823 50595371
Sepsis 27.95 17.37 68 8862 132857 50463337
Pain 27.82 17.37 37 8893 578866 50017328
Off label use 27.68 17.37 160 8770 474266 50121928
Incorrect route of product administration 26.98 17.37 24 8906 18642 50577552
Perforation 26.89 17.37 9 8921 955 50595239
Maternal exposure during delivery 26.52 17.37 9 8921 997 50595197
Product packaging confusion 26.18 17.37 6 8924 154 50596040
Ischaemic stroke 26.07 17.37 22 8908 15926 50580268
Circulatory collapse 25.56 17.37 24 8906 19976 50576218
Seizure 25.52 17.37 61 8869 117813 50478381
Joint swelling 25.51 17.37 6 8924 245280 50350914
Tonic clonic movements 24.70 17.37 9 8921 1228 50594966
Ureteric perforation 24.56 17.37 4 8926 14 50596180
Enterococcal sepsis 24.43 17.37 9 8921 1266 50594928
Neutropenic sepsis 24.13 17.37 20 8910 14127 50582067
Infusion site discomfort 23.71 17.37 8 8922 870 50595324
Abdominal discomfort 23.43 17.37 6 8924 231635 50364559
Infusion site warmth 23.40 17.37 9 8921 1425 50594769
Myoclonic epilepsy 22.89 17.37 8 8922 967 50595227
Alanine aminotransferase increased 22.76 17.37 49 8881 88310 50507884
Toxic epidermal necrolysis 22.72 17.37 23 8907 20969 50575225
Acute generalised exanthematous pustulosis 22.66 17.37 16 8914 8922 50587272
Product dose omission issue 22.35 17.37 3 8927 183835 50412359
Haemoptysis 22.34 17.37 25 8905 25548 50570646
Urine ketone body present 22.32 17.37 10 8920 2323 50593871
Meningitis aseptic 22.29 17.37 12 8918 4140 50592054
Hepatic function abnormal 22.04 17.37 28 8902 32653 50563541
Febrile neutropenia 21.63 17.37 51 8879 97616 50498578
Uterine haemorrhage 21.56 17.37 11 8919 3404 50592790
Drug intolerance 21.55 17.37 6 8924 219098 50377096
Embolic stroke 21.35 17.37 11 8919 3473 50592721
Product use in unapproved indication 20.96 17.37 56 8874 115763 50480431
Infusion site rash 20.40 17.37 8 8922 1334 50594860
Atrial thrombosis 19.66 17.37 8 8922 1469 50594725
Platelet count increased 19.65 17.37 18 8912 14522 50581672
PCO2 abnormal 19.49 17.37 4 8926 60 50596134
Nosocomial infection 19.42 17.37 8 8922 1514 50594680
Amylase increased 19.30 17.37 12 8918 5418 50590776
Hyperaesthesia 19.27 17.37 14 8916 8159 50588035
Blood pressure decreased 19.22 17.37 35 8895 55874 50540320
Stevens-Johnson syndrome 18.54 17.37 21 8909 21731 50574463
Cancer pain 18.29 17.37 9 8921 2578 50593616
Pyrexia 18.21 17.37 122 8808 380081 50216113
Multiple organ dysfunction syndrome 17.93 17.37 32 8898 50305 50545889
White blood cell count increased 17.88 17.37 29 8901 42211 50553983
HER2 positive breast cancer 17.62 17.37 5 8925 306 50595888

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myoclonus 77.28 17.89 44 6624 13265 29554594
Febrile neutropenia 74.54 17.89 108 6560 112132 29455727
Factor VIII inhibition 70.92 17.89 16 6652 296 29567563
Anaphylactic reaction 60.60 17.89 50 6618 27523 29540336
Generalised tonic-clonic seizure 57.99 17.89 42 6626 19097 29548762
Haemorrhage 51.62 17.89 57 6611 45015 29522844
Vasodilatation 47.86 17.89 15 6653 1009 29566850
Post procedural hypotension 42.56 17.89 8 6660 56 29567803
Platelet count decreased 40.28 17.89 79 6589 104593 29463266
Wrong product administered 34.69 17.89 18 6650 4513 29563346
Upper respiratory tract inflammation 33.82 17.89 13 6655 1607 29566252
Cerebral infarction 33.17 17.89 34 6634 24641 29543218
Interstitial lung disease 33.16 17.89 52 6616 57666 29510193
Haemoptysis 32.16 17.89 37 6631 30513 29537346
Mesenteric vascular insufficiency 31.98 17.89 7 6661 112 29567747
Haemoglobin increased 29.63 17.89 14 6654 2872 29564987
Muscle haemorrhage 27.60 17.89 14 6654 3348 29564511
Haemarthrosis 26.94 17.89 13 6655 2793 29565066
Haemophilia 26.35 17.89 4 6664 5 29567854
Hepatic function abnormal 24.83 17.89 37 6631 39222 29528637
Vascular stent thrombosis 24.78 17.89 12 6656 2598 29565261
Post procedural haemorrhage 23.96 17.89 17 6651 7474 29560385
Cerebral haemorrhage 23.38 17.89 32 6636 31394 29536465
Pneumonia 22.64 17.89 136 6532 320036 29247823
Myoclonic epilepsy 20.98 17.89 8 6660 967 29566892
Chronic pulmonary histoplasmosis 20.12 17.89 3 6665 3 29567856
Oesophageal haemorrhage 19.68 17.89 8 6660 1145 29566714
Myelodysplastic syndrome 19.48 17.89 22 6646 17772 29550087
Hepatic cyst ruptured 18.90 17.89 3 6665 6 29567853
Toxicity to various agents 18.52 17.89 8 6660 173653 29394206

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myoclonus 120.03 14.54 74 14896 25044 64458718
Wrong product administered 98.69 14.54 44 14926 7676 64476086
Generalised tonic-clonic seizure 97.71 14.54 78 14892 39779 64443983
Vasodilatation 94.87 14.54 33 14937 2985 64480777
Anaphylactic reaction 88.96 14.54 94 14876 68570 64415192
Haemorrhage 79.47 14.54 95 14875 79256 64404506
Platelet count decreased 70.88 14.54 134 14836 167577 64316185
Febrile neutropenia 67.33 14.54 140 14830 187517 64296245
Purpura 63.15 14.54 43 14927 17203 64466559
Cerebral infarction 60.03 14.54 60 14910 40984 64442778
Factor VIII inhibition 59.21 14.54 14 14956 311 64483451
Vaginal haemorrhage 58.69 14.54 43 14927 19301 64464461
Melaena 58.40 14.54 67 14903 53481 64430281
Renal cortical necrosis 55.28 14.54 13 14957 282 64483480
Status epilepticus 54.36 14.54 43 14927 21620 64462142
Pulmonary embolism 52.24 14.54 109 14861 146247 64337515
Heavy menstrual bleeding 51.21 14.54 33 14937 12044 64471718
Post procedural hypotension 47.62 14.54 9 14961 63 64483699
Haemoptysis 46.27 14.54 57 14913 48991 64434771
Myoclonic epilepsy 44.51 14.54 16 14954 1592 64482170
Fatigue 43.31 14.54 67 14903 748663 63735099
Toxicity to various agents 41.93 14.54 16 14954 363497 64120265
Aplastic anaemia 40.11 14.54 30 14940 13890 64469872
Hepatic function abnormal 38.47 14.54 60 14910 64253 64419509
Haemoglobin increased 37.37 14.54 20 14950 5181 64478581
Upper respiratory tract inflammation 37.26 14.54 18 14952 3764 64479998
Thrombocytopenia 36.01 14.54 124 14846 223677 64260085
Deep vein thrombosis 35.96 14.54 77 14893 105105 64378657
Incorrect route of product administration 33.95 14.54 34 14936 23264 64460498
Rash maculo-papular 32.58 14.54 47 14923 46979 64436783
Product packaging confusion 32.10 14.54 8 14962 223 64483539
Seizure 31.82 14.54 98 14872 166794 64316968
Biliary sepsis 31.41 14.54 12 14958 1416 64482346
Infusion site scar 31.01 14.54 8 14962 257 64483505
Mesenteric vascular insufficiency 30.40 14.54 7 14963 138 64483624
Cerebral haemorrhage 29.63 14.54 47 14923 51043 64432719
Rectal haemorrhage 29.35 14.54 52 14918 61765 64421997
Retinal artery occlusion 29.15 14.54 14 14956 2889 64480873
Tri-iodothyronine free decreased 28.56 14.54 8 14962 353 64483409
Hereditary angioedema 28.11 14.54 15 14955 3861 64479901
Muscle haemorrhage 27.59 14.54 17 14953 5736 64478026
Tonic clonic movements 27.56 14.54 12 14958 1977 64481785
Pain 26.99 14.54 55 14915 553456 63930306
Coronary artery thrombosis 26.30 14.54 13 14957 2856 64480906
Epistaxis 26 14.54 65 14905 98066 64385696
Blood pressure decreased 25.96 14.54 60 14910 86139 64397623
Rash erythematous 25.83 14.54 43 14927 48590 64435172
Haemoglobin decreased 25.42 14.54 101 14869 194962 64288800
Circulatory collapse 25.27 14.54 35 14935 33697 64450065
Maternal exposure during delivery 25.18 14.54 9 14961 881 64482881
Enterococcal sepsis 24.96 14.54 12 14958 2482 64481280
Weight decreased 24.92 14.54 18 14952 285721 64198041
Platelet count increased 24.91 14.54 26 14944 18670 64465092
Brain oedema 24.70 14.54 28 14942 22047 64461715
Acute left ventricular failure 24.69 14.54 10 14960 1377 64482385
Joint swelling 23.95 14.54 10 14960 215372 64268390
Drug intolerance 23.87 14.54 7 14963 187985 64295777
Post procedural haemorrhage 23.58 14.54 21 14949 12410 64471352
Infusion site warmth 23.55 14.54 9 14961 1063 64482699
Ureteric perforation 23.46 14.54 4 14966 14 64483748
Perforation 22.95 14.54 9 14961 1139 64482623
Infusion site discomfort 22.63 14.54 8 14962 758 64483004
Immune thrombocytopenia 21.97 14.54 22 14948 15044 64468718
Basophil count increased 21.86 14.54 9 14961 1291 64482471
Thoracotomy 21.69 14.54 5 14965 99 64483663
Uterine haemorrhage 21.62 14.54 11 14959 2568 64481194
Acute myocardial infarction 21.51 14.54 49 14921 69669 64414093
Interstitial lung disease 21.09 14.54 60 14910 97672 64386090
Haemorrhagic diathesis 20.78 14.54 14 14956 5500 64478262
Off label use 20.72 14.54 231 14739 632575 63851187
Alanine aminotransferase increased 20.58 14.54 75 14895 138956 64344806
Embolic stroke 20.54 14.54 15 14955 6696 64477066
Thrombotic microangiopathy 20.13 14.54 22 14948 16633 64467129
Chronic pulmonary histoplasmosis 20.03 14.54 3 14967 3 64483759
Infusion site rash 19.77 14.54 8 14962 1098 64482664
Myelodysplastic syndrome 19.74 14.54 28 14942 27551 64456211
Drug eruption 19.26 14.54 32 14938 36104 64447658
Haemarthrosis 19.05 14.54 13 14957 5216 64478546
Procedural haemorrhage 18.97 14.54 12 14958 4240 64479522
Vascular stent thrombosis 18.88 14.54 11 14959 3353 64480409
Hepatic cyst ruptured 18.81 14.54 3 14967 6 64483756
Neutropenic sepsis 18.72 14.54 25 14945 23247 64460515
Arthropathy 18.39 14.54 3 14967 120964 64362798
Acute myeloid leukaemia 18.37 14.54 27 14943 27436 64456326
Pyrexia 18.30 14.54 204 14766 558440 63925322
Drug hypersensitivity 18.23 14.54 17 14953 237798 64245964
PCO2 abnormal 18.22 14.54 4 14966 63 64483699
Abdominal discomfort 17.93 14.54 10 14960 182312 64301450
Multiple organ dysfunction syndrome 17.88 14.54 58 14912 101355 64382407
Intracardiac thrombus 17.70 14.54 11 14959 3770 64479992
Atrial thrombosis 17.22 14.54 10 14960 3032 64480730
Hyperaesthesia 17.20 14.54 16 14954 9998 64473764
Peripheral swelling 17.18 14.54 14 14956 209139 64274623
HER2 positive breast cancer 17.02 14.54 5 14965 262 64483500
Oesophageal haemorrhage 17.01 14.54 8 14962 1576 64482186
Pneumonia 16.83 14.54 201 14769 559375 63924387
Urine ketone body present 16.44 14.54 10 14960 3297 64480465
Aphasia 16.39 14.54 32 14938 40874 64442888
Anaphylactic shock 16.35 14.54 27 14943 30301 64453461
Cardiac failure congestive 16.32 14.54 5 14965 130575 64353187
Haemophilic arthropathy 16.24 14.54 4 14966 106 64483656
Bronchial artery embolisation 16.13 14.54 3 14967 19 64483743
Fibroma 15.91 14.54 6 14964 683 64483079
Product use in unapproved indication 15.90 14.54 82 14888 176536 64307226
Fall 15.90 14.54 47 14923 416779 64066983
Neutrophil count increased 15.76 14.54 24 14946 25150 64458612
Meningitis aseptic 15.73 14.54 12 14958 5718 64478044
White blood cell count increased 15.70 14.54 42 14928 65972 64417790
Sepsis 15.53 14.54 99 14871 230242 64253520
Weight increased 15.48 14.54 16 14954 213332 64270430
Pulmonary haemorrhage 15.30 14.54 17 14953 13092 64470670
Haemodynamic instability 15.15 14.54 18 14952 14894 64468868
Malignant neoplasm progression 15.14 14.54 59 14911 112812 64370950
Anaemia 15.09 14.54 144 14826 378536 64105226
Shock haemorrhagic 15.00 14.54 19 14951 16772 64466990

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B02AA02 BLOOD AND BLOOD FORMING ORGANS
ANTIHEMORRHAGICS
ANTIFIBRINOLYTICS
Amino acids
MeSH PA D000933 Antifibrinolytic Agents
MeSH PA D003029 Coagulants
MeSH PA D006401 Hematologic Agents
MeSH PA D006490 Hemostatics
FDA PE N0000175632 Decreased Fibrinolysis
FDA EPC N0000175634 Antifibrinolytic Agent
CHEBI has role CHEBI:48675 antifibrinolytic agent
CHEBI has role CHEBI:50248 hematologic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Contraception indication 13197004
Female hypogonadism syndrome indication 16041008
Endometriosis indication 129103003
Menorrhagia indication 386692008
Hemorrhaging in Hemophilia indication
Refractory melasma off-label use 36209000
Epistaxis off-label use 249366005
Hyperfibrinolysis Induced Hemorrhage off-label use
Prevention of Hemorrhage with Cardiovascular Instability from Cardiopulmonary Bypass - CABG off-label use
Postsurgical Hemorrhage off-label use
Heart valve disorder contraindication 368009 DOID:4079
Cerebral edema contraindication 2032001
Hypercholesterolemia contraindication 13644009
Subarachnoid intracranial hemorrhage contraindication 21454007
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Hyperlipidemia contraindication 55822004 DOID:1168
Benign mammary dysplasia contraindication 57993004
Obstructive hyperbilirubinemia contraindication 59848001
Thrombophlebitis contraindication 64156001 DOID:3875
Intermenstrual bleeding - irregular contraindication 64996003
Cerebral arterial thrombosis contraindication 71444005
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Malignant neoplasm of liver contraindication 93870000 DOID:3571
Deep venous thrombosis contraindication 128053003
Angina pectoris contraindication 194828000
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Cholestasis of pregnancy contraindication 235888006
Endometrial carcinoma contraindication 254878006 DOID:2871
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Malignant tumor of cervix contraindication 363354003 DOID:4362
Thromboembolic disorder contraindication 371039008
Cardiovascular event risk contraindication 395112001
Ligneous conjunctivitis contraindication 403435005
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Porphyria contraindication 418470004
Thrombosis contraindication 439127006
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Major Surgery with Prolonged Post-Operative Immobilization contraindication
Nonspecific Abnormal Papanicolaou Smear of Cervix contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.31 acidic
pKa2 10.7 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
650MG LYSTEDA AMRING PHARMS N022430 Nov. 13, 2009 RX TABLET ORAL 8022106 March 4, 2025 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
650MG LYSTEDA AMRING PHARMS N022430 Nov. 13, 2009 RX TABLET ORAL 8273795 March 4, 2025 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
650MG LYSTEDA AMRING PHARMS N022430 Nov. 13, 2009 RX TABLET ORAL 8487005 March 4, 2025 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
650MG LYSTEDA AMRING PHARMS N022430 Nov. 13, 2009 RX TABLET ORAL 8791160 March 4, 2025 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
650MG LYSTEDA AMRING PHARMS N022430 Nov. 13, 2009 RX TABLET ORAL 8809394 March 4, 2025 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
650MG LYSTEDA AMRING PHARMS N022430 Nov. 13, 2009 RX TABLET ORAL 8957113 March 4, 2025 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Plasminogen Enzyme INHIBITOR Kd 5.96 CHEMBL CHEMBL

External reference:

IDSource
4020569 VUID
N0000148271 NUI
D01136 KEGG_DRUG
4020569 VANDF
C0040613 UMLSCUI
CHEBI:48669 CHEBI
CHEMBL877 ChEMBL_ID
DB00302 DRUGBANK_ID
D014148 MESH_DESCRIPTOR_UI
5526 PUBCHEM_CID
2060 INN_ID
6573 IUPHAR_LIGAND_ID
6T84R30KC1 UNII
10691 RXNORM
5607 MMSL
80873 MMSL
d00529 MMSL
002073 NDDF
109006003 SNOMEDCT_US
386960009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cyklokapron HUMAN PRESCRIPTION DRUG LABEL 1 0013-1114 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 30 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 0517-0960 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 30 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 0591-3720 TABLET, FILM COATED 650 mg ORAL ANDA 25 sections
Tranexamic acid HUMAN PRESCRIPTION DRUG LABEL 1 14789-500 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 20 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 17478-017 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 17478-018 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 27 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 23155-166 INJECTION, SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 23155-524 INJECTION, SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 39822-1000 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 29 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 42192-605 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 13 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 42571-189 INJECTION 100 mg INTRAVENOUS ANDA 27 sections
TRANEXAMIC ACID HUMAN PRESCRIPTION DRUG LABEL 1 42571-314 INJECTION 100 mg INTRAVENOUS ANDA 27 sections
TRANEXAMIC ACID HUMAN PRESCRIPTION DRUG LABEL 1 43066-008 INJECTION 100 mg INTRAVENOUS ANDA 27 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 50090-4530 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 30 sections
tranexamic acid HUMAN PRESCRIPTION DRUG LABEL 1 50090-5072 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
TRANEXAMIC ACID HUMAN PRESCRIPTION DRUG LABEL 1 51662-1532 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 16 sections
TRANEXAMIC ACID IN SODIUM CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51754-0108 INJECTION, SOLUTION 10 mg INTRAVENOUS NDA 25 sections
Tranexamic Acid Human Prescription Drug Label 1 55150-188 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 27 sections
Lysteda HUMAN PRESCRIPTION DRUG LABEL 1 55566-2110 TABLET 650 mg ORAL NDA 28 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 60505-3638 TABLET 650 1 ORAL ANDA 25 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 60505-6169 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 28 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 60505-6169 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 28 sections
tranexamic acid HUMAN PRESCRIPTION DRUG LABEL 1 61990-0611 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 27 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 62559-265 TABLET 650 mg ORAL ANDA 29 sections
Tranexamic Acid Human Prescription Drug Label 1 63323-563 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 32 sections
Tranexamic Acid Human Prescription Drug Label 1 63323-563 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 32 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 63629-8599 TABLET, FILM COATED 650 mg ORAL ANDA 26 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 63629-8838 TABLET, FILM COATED 650 mg ORAL ANDA 26 sections
Tranexamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 63629-8838 TABLET, FILM COATED 650 mg ORAL ANDA 26 sections
Tranexamic Acid Human Prescription Drug Label 1 65145-106 INJECTION 100 mg INTRAVENOUS ANDA 27 sections